David Holland Net Worth

The estimated Net Worth of David Holland is at least $934 Thousand dollars as of 3 November 2021. Mr. Holland owns over 5,000 units of Alimera Sciences stock worth over $172,149 and over the last 14 years he sold ALIM stock worth over $185,865. In addition, he makes $576,458 as Chief Marketing Officer and Senior Vice President Corporate Communications and Managed Markets at Alimera Sciences.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Holland ALIM stock SEC Form 4 insiders trading

David has made over 16 trades of the Alimera Sciences stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of ALIM stock worth $20,400 on 3 November 2021.

The largest trade he's ever made was selling 30,000 units of Alimera Sciences stock on 17 May 2013 worth over $123,900. On average, David trades about 3,314 units every 57 days since 2010. As of 3 November 2021 he still owns at least 31,130 units of Alimera Sciences stock.

You can see the complete history of Mr. Holland stock trades at the bottom of the page.

David Holland biography

David R. Holland serves as Chief Marketing Officer and Senior Vice President Corporate Communications and Managed Markets of the Company. He is is one of our co-founders and currently serves as our Chief Marketing Officer, Senior Vice President Corporate Communications and Managed Markets. Mr. Holland served as the Vice President of Marketing from the founding of the Company in 2003 through August 2010, when he was appointed the Senior Vice President of Sales and Marketing, a position he held until January 2019. Prior to co-founding the Company, Mr. Holland served as the Vice President of Marketing of Novartis Ophthalmics from 1998 to 2003. In 1997, Mr. Holland served as Global Head of the Lens Business at CIBA Vision and in 1996, Global Head of the Lens Care Business of CIBA Vision. From 1992 to 1995, Mr. Holland served as the Director of Marketing for CIBA Vision Ophthalmics. From 1989 to 1991, Mr. Holland served as New Products Manager for CIBA Vision. From 1985 to 1989, Mr. Holland served as a Brand Assistant and Assistant Brand Manager of Procter and Gamble. Mr. Holland holds an A.B. in Politics from Princeton University.

What is the salary of David Holland?

As the Chief Marketing Officer and Senior Vice President Corporate Communications and Managed Markets of Alimera Sciences, the total compensation of David Holland at Alimera Sciences is $576,458. There are 3 executives at Alimera Sciences getting paid more, with Richard Eiswirth having the highest compensation of $977,025.

How old is David Holland?

David Holland is 56, he's been the Chief Marketing Officer and Senior Vice President Corporate Communications and Managed Markets of Alimera Sciences since 2018. There are 8 older and 5 younger executives at Alimera Sciences. The oldest executive at Alimera Sciences Inc. is James Largent, 70, who is the Lead Independent Director.

What's David Holland's mailing address?

David's mailing address filed with the SEC is 6310 TOWN SQUARE, SUITE 400, , ALPHARETTA, GA, 30005.

Insiders trading at Alimera Sciences

Over the last 14 years, insiders at Alimera Sciences have traded over $14,704,529 worth of Alimera Sciences stock and bought 8,598,915 units worth $59,337,384 . The most active insiders traders include Capital, Llc Armistice Capi..., Nicole Vitullo, and Jesse I Treu. On average, Alimera Sciences executives and independent directors trade stock every 32 days with the average trade being worth of $468,137. The most recent stock trade was executed by Partners Lpjohnson David Ed... on 14 September 2023, trading 579,000 units of ALIM stock currently worth $1,962,810.

What does Alimera Sciences do?

alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.

Complete history of Mr. Holland stock trades at Alimera Sciences

Alimera Sciences executives and stock owners

Alimera Sciences executives and other stock owners filed with the SEC include:

• Richard Eiswirth,
  President, Chief Executive Officer, Director
• C. Daniel Myers,
  Non-Executive Chairman of the Board
• Richard S. Eiswirth Jr.,
  Pres, CEO & Director
• David Holland,
  Chief Marketing Officer and Senior Vice President Corporate Communications and Managed Markets
• Philip Ashman,
  Chief Operating Officer, Senior Vice President - Commercial Operations Europe
• David R. Holland,
  Co-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets
• Dr. Philip Ashman,
  COO & Sr. VP of Commercial Operations - Europe
• Charles Daniel Myers,
  Non-Exec. Chairman & Consultant
• James Largent,
  Lead Independent Director
• John Marco,
  Investor Relations
• Mary Szela,
  Independent Director
• John Snisarenko,
  Independent Director
• Peter Pizzo,
  Independent Director
• Garheng Kong,
  Independent Director
• Brian Halak,
  Independent Director
• Samer Kaba,
  Chief Medical Officer
• Phil Jones,
  Chief Financial Officer
• Dr. David Dyer,
  Chief Retina Specialist
• Christopher S. Visick,
  VP, Gen. Counsel & Sec.
• J. Philip Jones,
  Chief Financial Officer
• Calvin W. Roberts,
  Director
• Glen Bradley,
  Director
• James E Deerfield Mgmt L.P....,
  
• Mark J Brooks,
  Director
• Kenneth Green,
  SVP & Chief Scientific Officer
• L.P.Mitchell Kateo'driscoll...,
  
• Alto Investors Lp Palo,
  
• Russell Skibsted,
  Chief Financial Officer & SVP
• Capital, Llc Armistice Capi...,
  
• Patrick Lee,
  10% owner
• Management Viii, L.L.C.Sofi...,
  
• Partners Vi, L.P.Blair Jame...,
  
• Vi Associates, L.P.Blair Ja...,
  
• Jesse I Treu,
  10% owner
• Venture Management Co Iv Ll...,
  
• Philip R Tracy,
  Director
• Susan Caballa,
  SEE REMARKS
• Kathleen K Schoemaker,
  10% owner
• Partners Vi, L.P. Domain,
  10% owner
• James C Blair,
  10% owner
• Nicole Vitullo,
  10% owner
• Anders D Hove,
  Director
• Bryce Youngren,
  Director
• Brian H Dovey,
  10% owner
• Vi Associates, L.P. Dp,
  10% owner
• Associates Iv L P Venrock M...,
  
• Associates Vi, Llc Mumma Mi...,
  
• Associates Vii, Llc Mumma M...,
  
• Associates V, Llc Mumma Mit...,
  
• L.P.Bock Louis Cmitchell Ka...,
  
• Adam Morgan,
  Director
• Stanley Morgan,
  10% owner
• Todd Michael Wood,
  President of U.S. Operations
• Roger Sawhney,
  Director
• Adam Velan Capital Investme...,
  
• Partners Lpjohnson David Ed...,
  
• Jason M. Werner,
  Chief Operating Officer
• Erin Parsons,
  
• Michael Kaseta,
  
• Ross D De Mont,
  
• Margaret Pax,
  
• Elliot Maltz,
  Chief Financial Officer